1 Diezi M, Gambazzi F, Hillinger S. Der parapneumonische Erguss und das Pleuraempyem aus thoraxchirurgischer Sicht. Schweiz Med Forum. 2018;18(10):222–9.
2 Cameron R, Davies HR. Intra-pleural fibrinolytic therapy versusconservative management in the treatment of adult parapneumonic effusions and empyema. Cochrane Database Syst Rev. 2008;16:CD002 312.
3 Rahman NM, Maskell NA, West Al, et al. Intrapleural Use of Tissue Plasminogen Activator and DNase in Pleural Infection. N Engl J Med. 2011;356:518–26.
4 Piccolo F, Pitman N, Bhatnagar R et al. Intrapleural Tissue Plasminogen Activator and Deoxiribonuclease for Pleural Infection. Ann Am Thorac Soc. 2014;11(9):1419–25.
5 Mehta HJ, Biswas A, Penley A, et al. Management of Intrapleural Sepsis with Once Daily Use of Tissue Plasminogen Activator and Deoxiribonuclease. Respiration. 2016;91:101–6.
6 Davies HE, Davies RJ, Davies CW, et al. Management of Pleural Infection in Adults: British Thoracic Society Pleural Disease Guideline 2010. Thorax. 2010;65 Suppl 2:ii41–53.
7 Rahman NM, Maskell NA, Davies CW, et al. The Relationship between Chest Tube Size and Clinical Outcome in Pleural Infection. Chest. 2010;137(3)536–43.